ERBB2 and breast cancer: An ongoing phase II trial (NCT05660083) is investigating the combination of an inducible nitric oxide synthase (iNOS) inhibitor and nab-paclitaxel along with alpelisib in patients with HER-2-negative, metastatic, or locally advanced metaplastic BC.